This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

5 Most M&A Crazy Companies Since the Financial Crisis

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Johnson & Johnson (JNJ - Get Report)

In April, Johnson & Johnson bought medical device maker Synthes for $21.3 billion in the biggest merger in its 125 year history. The purchase added to a run of eight other crisis-time acquisitions over $250 million in size that's brought its deals total to $25.2 billion.

With Synthes, Johnson & Johnson took over a high quality maker of medical devices like screws and bone grafts, bolstering a health products unit that has recalled over 50 products since 2010, according to Bloomberg reports. Currently, J&J is the second largest maker of health products to Pfizer.

While J&J's underperformed its drug and medical products competitor, gaining just 5% year-to-date compared with Pfizer's 13% return, the company's shares are only down 10% from its pre-crisis highs in contrast to Pfizer's near 30% loss. Even after the deal, Moody's maintained J&J's AAA rating.

In total both Pfizer, with its $68 billion acquisition of Wyeth and Merck's (MRK - Get Report) $41 billion takeover of Schering-Plough in 2009 have cut larger deals than J&J, but neither has bought many other companies. In 2010, Merck ended an $8.2 billion animal health services joint venture with Sanofi Aventis (SNY) over complications to the deal like divestitures.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GS $191.68 1.00%
GE $26.10 0.44%
JNJ $103.16 0.63%
HPQ $34.92 0.23%
MRK $58.58 0.06%

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs